Pseudomonas aeruginosa

Susceptibility of clinical Enterobacterales and Pseudomonas aeruginosa isolates to ceftazidimeavibactam in Russia: multicenter local laboratory databased surveillance

Objective. To assess the in vitro activity of ceftazidime-avibactam against clinical Enterobacterales and Pseudomonas aeruginosa isolates in various regions of Russia based on results of local susceptibility testing by disk diffusion method. Materials and Methods. Overall, 160 laboratories located in 61 Russian cities participated in this surveillance during 2018-2020. All consecutive clinical isolates of Enterobacterales and Pseudomonas aeruginosa in each participating laboratory were included in the study. Ceftazidime-avibactam susceptibility testing was done by disc-diffusion method in accordance with current EUCAST recommendations.

Imaging of the bacterial interactions in lung co-infection in cystic fibrosis patients

Objective. To identify bacterial interactions at the site of infection in cystic fibrosis patients and to assess their possible effects on the course of infection. Materials and Methods. The following strains were used in this study: Alcaligenes faecalis LGBP strain, isolated from the environment; clinical isolates of Pseudomonas aeruginosa; Achromobacter xylosoxidans, Acinetobacter baumannii, Alcaligenes faecalis, and Bacillus subtilis strains; the standard laboratory P. aeruginosa PAO1 strain and its lysogens by temperate bacteriophages of various species, and its phageresistant mutants.

Potentiation of antimicrobial activity of colistin with antibiotics of different groups against multidrug- and extensively drug-resistant strains of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa

Objective. To reveal antibiotics being capable of potentiating the antimicrobial activity of colistin against multidrug- and extensively drug-resistant strains of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Materials and Methods. The minimum inhibitory concentrations (MIC) of colistin alone and in combination with fixed concentrations of antibiotics of different groups were determined for 272 multidrug- and extensively drug-resistant strains of K. pneumoniae, A. baumannii and P. aeruginosa. Bactericidal activity of colistin, carbapenems, clarithromycin and their combinations were also determined at fixed PK/PD breakpoint concentrations of antibiotics.

Antimicrobial resistance, carbapenemase production, and genotypes of nosocomial Pseudomonas aeruginosa isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”

Objective. Objectives. To assess the rates of antibiotic resistance, production of acquired carbapenemases, genotypes and prevalence of «international high-risk clones» among nosocomial strains of Pseudomonas aeruginosa isolated in various regions of Russia within the «MARATHON 2015–2016» study. Materials and Methods. A total of 1006 non-duplicate nosocomial isolates of P. aeruginosa collected in 44 hospitals from 25 cities in Russia in 2015–2016 were studied. Species identification of isolates was performed by means of MALDI-TOF mass-spectrometry.

Pseudomonas aeruginosa in the etiology of infections in hospitalized patients

Objective. To study the etiological role and antimicrobial susceptibility of Pseudomonas aeruginosa in one tertiary care hospital with analysis of the influence of antimicrobial stewardship implementation. Materials and Methods. In 2013 primary microbiological evaluation was performed. In 2014 antimicrobial stewardship program was implemented. The impact of the introduction of microbiological monitoring system and antimicrobial stewardship program was evaluated. Results. In total, 461 P. aeruginosa strains were isolated during the study period.

Genotypes and metallo-beta-lactamases carriage in carbapenem-resistant Pseudomonas aeruginosa isolated from children in Moscow

Objective. To characterize the population structure and determine the genetic mechanisms of carbapenem resistance in nosocomial isolates of P. aeruginosa collected in Moscow in 2012-2016. Materials and methods. Carbapenem-resistant isolates were collected in two pediatric hospitals in Moscow. Antibiotics susceptibility of P. aeruginosa isolates was assessed using the E-tests and disk-diffusion method. Multilocus sequence typing (MLST) was used for genotyping of the isolates. The presence of metallo-betalactamase (MBL) genes was determined using real-time PCR.

Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper …

Review of the Guidelines of the Spanish Society of Chemotherapy on antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa

P. aeruginosa is not only intrinsically resistant to many groups of antimicrobials, but is also extremely capable in acquiring resistance to almost all antibacterial agents that are used for the therapy of infections caused by this pathogen, making …

Susceptibility to antibiotic combinations among nosocomial carbapenemase-producing Gram-negative bacteria isolated in Belarus

Objective. To assess a susceptibility to antibiotic combinations in nosocomial carbapenemase-producing Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii isolates using a modified method of multiple combination bactericidal testing (MCBT). Materials and Methods. A total of 178 isolates (63 K. pneumoniae isolates, 31 P. aeruginosa isolates, 84 A. baumannii isolates) obtained in the 2013-2017 from hospitalized patients in 28 public health organizations in 4 Belarus regions were included in the study.

Pseudomonas aeruginosa: the history of one of the most successful nosocomial pathogens in Russian hospitals

Pseudomonas aeruginosa is recognized as one of the six most important pathogens in terms of antimicrobial resistance («ESKAPE» pathogens), and included by WHO in the group of microorganisms for which the need for development of new antimicrobial …